Edward J. Benz JR - 01 Dec 2022 Form 4 Insider Report for Renovacor, Inc. (RCOR)

Role: Director
Signature: /s/ Joseph Carroll, as attorney-in-fact
Issuer symbol: RCOR
Transactions as of: 01 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Dec 2022, 20:22:54 UTC
Previous filing: 17 Oct 2022
Next filing: 23 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCOR	Common Stock	Award		+3,586			3,586	01 Dec 2022	Direct	F1
transaction	RCOR	Common Stock	Disposed to Issuer		-3,586	-100%		0	01 Dec 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCOR	Stock Option	Disposed to Issuer	$0	-9,060	-100%	$0.000000^*	0	01 Dec 2022	Common Stock	9,060		Direct	F3, F4
transaction	RCOR	Stock Option	Disposed to Issuer	$0	-24,000	-100%	$0.000000^*	0	01 Dec 2022	Common Stock	24,000		Direct	F3, F4
transaction	RCOR	Stock Option	Disposed to Issuer	$0	-12,000	-100%	$0.000000^*	0	01 Dec 2022	Common Stock	12,000		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Edward J. Benz JR is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger contemplated by the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement").
F2	The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement).
F3	Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F4	Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.